(RPRX) Royalty Pharma - Performance 20.5% in 12m
Compare RPRX with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-25.42%
#77 in Group
Rel. Strength
77.84%
#1771 in Universe
Total Return 12m
20.45%
#33 in Group
Total Return 5y
-18.66%
#73 in Group
P/E 16.3
31th Percentile in Group
P/E Forward 10.0
30th Percentile in Group
PEG 2.18
78th Percentile in Group
FCF Yield 11.7%
(?) Percentile in Group
12m Total Return: RPRX (20.5%) vs XLV (-0.5%)

5y Drawdown (Underwater) Chart

Top Performers in Pharmaceuticals
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
CORT NASDAQ Corcept Therapeutics |
10.2% | 175% | 405% | 55.8 | 41 | 0.61 | 61.4% | 10.7% |
LLY NYSE Eli Lilly |
2.12% | 13.3% | 466% | 62.7 | 31.5 | 1.05 | 40.3% | 34.5% |
NVS NYSE Novartis |
-1.21% | 24.1% | 59.8% | 18 | 12.9 | 1.23 | 36.2% | 11% |
SFZN SW Siegfried Holding |
-2.09% | 1.78% | 95.3% | 24.1 | 22.1 | 1.41 | 66.7% | 72.5% |
SUPN NASDAQ Supernus Pharmaceuticals |
-4.71% | 6.55% | 74.3% | 24 | 20.2 | 1.47 | -20.8% | -17% |
SOBI ST Swedish Orphan Biovitrum |
-8.43% | 1.39% | 42.8% | 23.3 | 18.7 | 1.44 | 11.8% | 14.7% |
SAN PA Sanofi |
-15.7% | 10.9% | 24.2% | 21.9 | 11.6 | 0.93 | -22.1% | -24.8% |
NOVN SW Novartis |
-7.92% | 11.1% | 33.1% | 17.9 | 12.8 | 1.22 | 36.2% | 11.2% |
Performance Comparison: RPRX vs XLV vs S&P 500
XLV (Health Care Sector SPDR ETF) is the Sector Benchmark for RPRX
Total Return (including Dividends) | RPRX | XLV | S&P 500 |
---|---|---|---|
1 Month | -2.42% | -7.37% | -5.89% |
3 Months | 8.31% | -4.55% | -12.45% |
12 Months | 20.45% | -0.54% | 6.72% |
5 Years | -18.66% | 46.59% | 101.06% |
Trend Score (consistency of price movement) | RPRX | XLV | S&P 500 |
1 Month | -17.5% | -82.6% | -74.5% |
3 Months | 23.6% | -37.8% | -88.2% |
12 Months | 47.7% | -1.6% | 66.1% |
5 Years | -78.4% | 90.1% | 84.3% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XLV | vs. S&P 500 |
1 Month | #47 | 5.34% | 3.68% |
3 Month | #24 | 13.5% | 23.7% |
12 Month | #33 | 21.1% | 12.9% |
5 Years | #74 | -44.4% | -55.0% |
FAQs
Does RPRX Royalty Pharma outperforms the market?
Yes,
over the last 12 months RPRX made 20.45%, while its related Sector, the Health Care Sector SPDR (XLV) made -0.54%.
Over the last 3 months RPRX made 8.31%, while XLV made -4.55%.
Over the last 3 months RPRX made 8.31%, while XLV made -4.55%.
Performance Comparison RPRX vs Indeces and Sectors
RPRX vs. Indices RPRX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 3.44% | 3.47% | 27.6% | 13.7% |
US NASDAQ 100 | QQQ | 4.30% | 3.86% | 28.2% | 14.9% |
US Dow Jones Industrial 30 | DIA | 4.61% | 3.40% | 27.1% | 15.1% |
German DAX 40 | DAX | -1.92% | 6.98% | 10.6% | 2.24% |
Shanghai Shenzhen CSI 300 | CSI 300 | 2.73% | 5.08% | 25.4% | 14.6% |
Hongkong Hang Seng | HSI | -0.85% | 7.40% | 26.1% | 4.23% |
India NIFTY 50 | INDA | -0.93% | -7.19% | 25.2% | 17.4% |
Brasil Bovespa | EWZ | -0.12% | 2.66% | 24.7% | 29.9% |
RPRX vs. Sectors RPRX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 3.19% | 3.24% | 18.8% | 6.91% |
Consumer Discretionary | XLY | 4.31% | 1.50% | 24.9% | 11.2% |
Consumer Staples | XLP | 0.14% | -5.62% | 17.4% | 6.51% |
Energy | XLE | -1.28% | 7.66% | 26.6% | 30.7% |
Financial | XLF | 2.07% | 2.09% | 19.5% | 1.50% |
Health Care | XLV | 3.04% | 4.95% | 29.0% | 21.0% |
Industrial | XLI | 2.32% | 2.28% | 27.6% | 15.1% |
Materials | XLB | 1.72% | 4.23% | 34.7% | 28.0% |
Real Estate | XLRE | -1.90% | 0.47% | 26.3% | 3.34% |
Technology | XLK | 4.80% | 6.51% | 34.5% | 21.7% |
Utilities | XLU | 0.13% | -2.0% | 21.9% | -3.92% |
Aerospace & Defense | XAR | 1.75% | -2.46% | 17.9% | -3.71% |
Biotech | XBI | -0.12% | 9.46% | 42.2% | 29.4% |
Homebuilder | XHB | 2.49% | 4.42% | 45.5% | 29.6% |
Retail | XRT | 1.74% | -0.31% | 32.3% | 24.8% |